Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL187910 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL490446 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL661763 | 0.91 | SMN1; SMN2 (0.43) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL11302194 | 0.80 | TSHR (0.35) | SMN1; SMN2KMT2ATSHRMEN1ALDH1A1 | |
| SCHEMBL25741000 | 0.80 | KMT2A (0.32) | SMN1; SMN2KMT2A | |
| SCHEMBL5124368 | 0.80 | CA1 (0.43) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL4420430 | 0.80 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ACA1CA2CA14 | |
| SCHEMBL4867613 | 0.78 | — | — | |
| SCHEMBL50447 | 0.78 | — | — | |
| SCHEMBL30415488 | 0.78 | SMN1; SMN2 (0.39) | SMN1; SMN2KMT2ACA1CA2CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169950-B2 | Method for producing monocarbonyl compounds or biscarbonyl compounds or hydroxyl compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-01-30 | — | — | US | disclosed |
| US-20040073041-A1 | Method for producing monocarbonyl compounds or biscarbonyl compounds or hydroxyl compounds | DSM FINE CHEMICALS AUSTRIA NFG GMBH & COKG (AT) | 2004-04-15 | — | — | US | disclosed |
| US-4769464-A | Process for the preparation of monocarbonyl or biscarbonyl compounds | CHEMIE LINZ GESELLSCHAFT M.B.H. (AT) | 1988-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040073041-A1 | Method for producing monocarbonyl compounds or biscarbonyl compounds or hydroxyl compounds | OXER1, FHIT, HAO2 | SMN1; SMN2 4471/4885KMT2A 1517/4885CA1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.